Since the introduction of organized cytological screening in Sweden, most women currently presenting with cervical cancer are those who have not attended the programme and who have no cytological screening history. The aims of this study were: (i) to measure the response rate among women not attending organized cytological screening who were offered a device for self-sampling a vaginal smear at home; (ii) to examine the prevalence of high-risk human papilloma virus (HPV) among women performing self-sampling. Women aged 35–50 years, who had not participated in organized cytological screening for more than 6 years, were offered the opportunity to collect vaginal samples at home using a self-sampling device (Qvintip®). The material collected w...
We determined whether the participation rate for a brush-based cervicovaginal self-sampling device i...
IntroductionCervical cancer screening primarily with high risk human papillomavirus (hr-HPV) proved ...
Cervical cancer is the fourth most common reason for cancer death amongst women worldwide, with 500 ...
Since the introduction of organized cytological screening in Sweden, most women currently presenting...
Cervical cancer is preventable through gynecological screening. To promote participation among non-a...
Background: The efficacy of cervical cancer screening programs is dependent on the participation rat...
BACKGROUND: Most women with cervical cancer have not participated in Pap-smear screening. Self-sampl...
AbstractIn France, about 40% of women aged 25–65 years do not participate in regular screening and t...
OBJECTIVE:Self-sampling to test for high risk human papilloma virus (HPV) is becoming an increasingl...
In 2017 the cervical cancer screening program in The Netherlands will be revised. Cervical smears wi...
Aim: Self-sampling devices for oncogenic human papillomavirus (HPV) testing may be useful for improv...
AbstractBackgroundSelf-sampling for high-risk human papillomavirus (hrHPV) testing is accepted by up...
This review elaborates on the accuracy and feasibility of human papillomavirus (HPV) self-sampling, ...
International audienceIn France, cervical cancer screening based on cervical smear has a participati...
Increasing attendance to screening offers the best potential for improving the effectiveness of well...
We determined whether the participation rate for a brush-based cervicovaginal self-sampling device i...
IntroductionCervical cancer screening primarily with high risk human papillomavirus (hr-HPV) proved ...
Cervical cancer is the fourth most common reason for cancer death amongst women worldwide, with 500 ...
Since the introduction of organized cytological screening in Sweden, most women currently presenting...
Cervical cancer is preventable through gynecological screening. To promote participation among non-a...
Background: The efficacy of cervical cancer screening programs is dependent on the participation rat...
BACKGROUND: Most women with cervical cancer have not participated in Pap-smear screening. Self-sampl...
AbstractIn France, about 40% of women aged 25–65 years do not participate in regular screening and t...
OBJECTIVE:Self-sampling to test for high risk human papilloma virus (HPV) is becoming an increasingl...
In 2017 the cervical cancer screening program in The Netherlands will be revised. Cervical smears wi...
Aim: Self-sampling devices for oncogenic human papillomavirus (HPV) testing may be useful for improv...
AbstractBackgroundSelf-sampling for high-risk human papillomavirus (hrHPV) testing is accepted by up...
This review elaborates on the accuracy and feasibility of human papillomavirus (HPV) self-sampling, ...
International audienceIn France, cervical cancer screening based on cervical smear has a participati...
Increasing attendance to screening offers the best potential for improving the effectiveness of well...
We determined whether the participation rate for a brush-based cervicovaginal self-sampling device i...
IntroductionCervical cancer screening primarily with high risk human papillomavirus (hr-HPV) proved ...
Cervical cancer is the fourth most common reason for cancer death amongst women worldwide, with 500 ...